Trial Spotlight: A Closer Look at ECOG-ACRIN’s Lung Cancer Studies
December 19, 2023Opportunity Knocks: Harnessing the Skills of Advanced Practice Providers for Cancer Clinical Research
December 19, 202346 Member Networks and Programs Receive Commendations in 2023 for Research Performance
Each year, the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) conducts an Institution Evaluation in which a subset of Principal Investigator (PI) Committee members and senior administrators meet to evaluate the performance of ECOG-ACRIN member networks and programs. The exceptional staff in the Membership Department facilitates the process—encompassing nearly 1500 individual research institutions in total, comprising 140 research programs. Through this annual review, principal investigators and research personnel stay informed about the many scientific and administrative components that comprise ECOG-ACRIN's expectations for retaining membership in the Group. In addition, the evaluation ensures that member institutions maintain ECOG-ACRIN's high standards to conduct cancer research with and through the Group.
Data from the previous calendar year (2022) was evaluated. The following areas are part of the review: accrual, clinical data quality and timeliness, compliance with requirements for submission of laboratory samples and images, scientific leadership, administrative contribution, and compliance with policies of both ECOG-ACRIN and the National Cancer Institute (NCI) through its National Clinical Trials Network audit process. The review committee is blinded to the identity of the institutions during this initial evaluation when they give a numerical rating to these categories. However, final unblinded assessments are based on both the objective data and discussions on the unique aspects of each institution that cannot be captured in a numerical rating.
For 2023, the review committee voted to commend the following 46 networks and NCI Community Oncology Research Programs (NCORPs). Group Co-Chairs Peter O'Dwyer, MD, and Mitchell Schnall, MD, PhD, recognized them during the General Session of the Fall 2023 Group Meeting.
Overall Outstanding Performance
Institution |
Principal Investigator |
Aultman Health Foundation/Timken Family Cancer Center |
Sunitha Vemulapalli, MD |
Delaware/Christiana Care NCORP |
Gregory A. Masters, MD |
Heartland Cancer Research NCORP |
Bryan A. Faller, MD |
Memorial Sloan Kettering Cancer Center |
Christopher E. Comstock, MD |
Metro-Minnesota Community Oncology Research Consortium NCORP |
David M. King, MD |
National Cancer Center Korea |
Ji-Youn Han, MD |
New York University/NYU Langone Perlmutter Cancer Center |
Catherine S. Diefenbach, MD |
Pacific Cancer Research Consortium NCORP |
Charles W. Drescher, MD |
Southeast Clinical Oncology Research Consortium NCORP |
Judith O. Hopkins, MD |
Stanford University/Standard Cancer Institute |
Melinda L. Telli, MD |
The Ohio State University/The James Cancer Hospital and Solove Research Institute |
James W. Rocco, MD, PhD |
University of California San Francisco/Helen Diller Family Comprehensive Cancer Center |
Thomas A. Hope, MD |
University of Massachusetts/UMass Cancer Center |
Jan Cerny, MD, PhD |
University of North Carolina at Chapel Hill/Lineberger Comprehensive Cancer Center |
Lisa A. Carey, MD |
University of Pennsylvania/Abramson Cancer Center |
Jennifer R. Eads, MD |
Wisconsin NCORP |
Kurt R. Oettel, MD |
Accrual, Scientific Contribution, and Administrative Participation
Institution |
Principal Investigator |
Emory University/Winship Cancer Institute |
Charles A. Staley III, MD |
Fox Chase Cancer Center |
Lori J. Goldstein, MD |
Gulf South Minority Underserved NCORP |
Augusto C. Ochoa, MD |
Johns Hopkins University/The Sidney Kimmel Comprehensive Cancer Center |
Julie R. Brahmer, MD |
Mayo Clinic Cancer Center |
Thomas M. Habermann, MD |
Rutgers Cancer Institute of New Jersey |
Howard S. Hochster, MD |
The University of Texas/MD Anderson Cancer Center |
PI in Transition |
University of Wisconsin/UW Carbone Cancer Center |
Kari B. Wisinski, MD |
Vanderbilt University/Vanderbilt-Ingram Cancer Center |
Jordan D. Berlin, MD |
Washington University at St. Louis/Siteman Cancer Center |
Barry A. Siegel, MD |
Accrual and Scientific Contribution
Institution |
Principal Investigator |
Dana-Farber/Harvard Cancer Center |
Frank S. Hodi, Jr., MD |
Froedtert & Medical College of Wisconsin |
Timothy S. Fenske, MD, MS |
Moffitt Cancer Center |
Jhanelle E. Gray, MD |
Yale University/Yale Cancer Center |
Barbara A. Burtness, MD |
Accrual and Data Management
Institution |
Principal Investigator |
Essentia Health NCORP |
Bret E. Friday, MD |
Georgia NCORP |
Guilherme Cantuária, MD, PhD |
Upstate Carolina NCORP |
James D. Bearden III, MD |
Accrual
Institution |
Principal Investigator |
AHN Cancer Center-Allegheny General Hospital |
Nathan Bahary, MD PhD |
Carle Cancer Center NCORP |
Kendrith M. Rowland, MD |
CERIM (Argentina) |
Daniel E. Lehrer, MD |
Cleveland Clinic Mercy Hospital |
Mitchell Haut, MD |
Dickstein Cancer Treatment Center at White Plains Hospital Center |
Karen B. Green, MD |
Memorial Hermann-Texas Medical Center |
Syed H. Jafri, MBBS |
Stamford Health Bennett Cancer Center |
Salvatore A. Del Prete, MD |
Tufts Medicine Cancer Center |
Rachel J. Buchsbaum, MD |
Yonsei University /Yonsei Cancer Hospital (South Korea) |
Joohyuk Sohn, MD |
Scientific Contribution
Institution |
Principal Investigator |
University of Washington/Fred Hutchinson Cancer Center |
Evan Y. Yu, MD |
Data Management
Institution |
Principal Investigator |
Aurora NCORP |
Thomas J. Saphner, MD |
Cancer Research Consortium of West Michigan NCORP |
Kathleen J. Yost, MD, BS |
Puerto Rico Minority Underserved NCORP |
Luis J. Santos Reyes, MD |